![Overall survival with sunitinib or pazopanib for first-line treatment... | Download Scientific Diagram Overall survival with sunitinib or pazopanib for first-line treatment... | Download Scientific Diagram](https://www.researchgate.net/publication/312066963/figure/fig3/AS:451472610598916@1484650866660/Overall-survival-with-sunitinib-or-pazopanib-for-first-line-treatment-of-metastatic-renal.png)
Overall survival with sunitinib or pazopanib for first-line treatment... | Download Scientific Diagram
![Table 3 from A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. | Semantic Scholar Table 3 from A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d3b16db9eabd1de88c5804ee9f58ba84a6374e66/5-Figure1-1.png)
Table 3 from A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. | Semantic Scholar
![Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer - Gynecologic Oncology Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer - Gynecologic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b6593146-cc93-4c8d-9262-ee8662d56d1d/gr1.jpg)
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer - Gynecologic Oncology
![The Impact of Pazopanib on the Cardiovascular System - Cody N. Justice, Mohamed H. Derbala, Tesla M. Baich, Amber N. Kempton, Aaron S. Guo, Thai H. Ho, Sakima A. Smith, 2018 The Impact of Pazopanib on the Cardiovascular System - Cody N. Justice, Mohamed H. Derbala, Tesla M. Baich, Amber N. Kempton, Aaron S. Guo, Thai H. Ho, Sakima A. Smith, 2018](https://journals.sagepub.com/cms/10.1177/1074248418769612/asset/images/large/10.1177_1074248418769612-fig1.jpeg)
The Impact of Pazopanib on the Cardiovascular System - Cody N. Justice, Mohamed H. Derbala, Tesla M. Baich, Amber N. Kempton, Aaron S. Guo, Thai H. Ho, Sakima A. Smith, 2018
![Overall survival with sunitinib or pazopanib for first-line treatment... | Download Scientific Diagram Overall survival with sunitinib or pazopanib for first-line treatment... | Download Scientific Diagram](https://www.researchgate.net/profile/Anil-Kapoor-4/publication/312066963/figure/fig2/AS:451472610598915@1484650866470/Progression-free-survival-for-cabozantinib-vs-sunitinib-in-advanced-renal-cell-carcinoma_Q320.jpg)
Overall survival with sunitinib or pazopanib for first-line treatment... | Download Scientific Diagram
![Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial - Annals of Oncology Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/536c1fd0-2dff-4fb8-b64a-91d10813c09a/gr2.jpg)
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial - Annals of Oncology
![Overall Survival. (A) OS, (B) Kaplan-Meier Curve for OS From First Line... | Download Scientific Diagram Overall Survival. (A) OS, (B) Kaplan-Meier Curve for OS From First Line... | Download Scientific Diagram](https://www.researchgate.net/publication/333382587/figure/fig1/AS:896249330929664@1590693900248/Overall-Survival-A-OS-B-Kaplan-Meier-Curve-for-OS-From-First-Line-Per-Sex-and-C.png)
Overall Survival. (A) OS, (B) Kaplan-Meier Curve for OS From First Line... | Download Scientific Diagram
![Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo‐controlled phase 2 trial with correlated serum proteomic signatures - Spigel - 2018 - Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo‐controlled phase 2 trial with correlated serum proteomic signatures - Spigel - 2018 -](https://acsjournals.onlinelibrary.wiley.com/cms/asset/65d7d81c-004e-4598-bbc4-3f072711f29f/cncr31290-fig-0002-m.jpg)
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo‐controlled phase 2 trial with correlated serum proteomic signatures - Spigel - 2018 -
![Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting](https://www.frontiersin.org/files/Articles/892156/fonc-12-892156-HTML/image_m/fonc-12-892156-t003.jpg)
Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting
![Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/35/6/3415/F4.large.jpg)
Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research
![Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study - Clinical Genitourinary Cancer Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study - Clinical Genitourinary Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/15d988c2-fd28-4197-afff-9905919aaf3d/fx1.jpg)
Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study - Clinical Genitourinary Cancer
![Table 3 from A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. | Semantic Scholar Table 3 from A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d3b16db9eabd1de88c5804ee9f58ba84a6374e66/6-Table3-1.png)
Table 3 from A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. | Semantic Scholar
![Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas | British Journal of Cancer Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-021-01448-0/MediaObjects/41416_2021_1448_Fig1_HTML.png)
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas | British Journal of Cancer
![Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence | Signal Transduction and Targeted Therapy Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence | Signal Transduction and Targeted Therapy](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41392-020-0199-6/MediaObjects/41392_2020_199_Fig1_HTML.png)
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence | Signal Transduction and Targeted Therapy
![Pazopanib as salvage therapy in metastatic renal cell carcinoma with hypercalcemic crisis and renal insufficiency: a case report and literature review - Chen - Translational Cancer Research Pazopanib as salvage therapy in metastatic renal cell carcinoma with hypercalcemic crisis and renal insufficiency: a case report and literature review - Chen - Translational Cancer Research](https://cdn.amegroups.cn/journals/pbpc/files/journals/3/articles/36758/public/36758-PB6-4681-R1.png/w300)
Pazopanib as salvage therapy in metastatic renal cell carcinoma with hypercalcemic crisis and renal insufficiency: a case report and literature review - Chen - Translational Cancer Research
![Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma](https://www.spandidos-publications.com/article_images/mco/7/3/mco-07-03-0454-g00.jpg)